低密度脂蛋白胆固醇水平与高强度抗栓治疗患者院内出血的关系:CCC-ACS项目
控制基线变量后,LDL-C与大出血呈非线性关系,低LDL-C水平风险更高;LDL-C<70 mg/dL与院内大出血风险增加独立相关(aOR 1.49,95%CI 1.21-1.84)。未发现LDL-C与缺血事件及死亡的剂量反应关系。
要点
- ACS接受PCI患者中,低LDL-C水平与院内大出血风险增加呈非线性关联。
- LDL-C<70 mg/dL者院内大出血风险增加(aOR 1.49,95%CI 1.21-1.84)。
- 替格瑞洛治疗者出血风险的LDL-C阈值为<88 mg/dL,氯吡格雷治疗者<54 mg/dL。
核心结论
- 在接受PCI的ACS患者中,LDL-C水平与院内大出血呈非线性关联,低LDL-C水平风险更高。
- 低LDL-C水平时替格瑞洛较氯吡格雷对大出血的影响更不利,高LDL-C水平时两者无差异。
研究设计与样本
- 研究记录615例大出血、218例缺血事件和337例死亡,采用多变量校正logistic回归及倾向性评分匹配分析。
主要发现
- 大出血与大出血呈非线性关系,低LDL-C水平风险更高;缺血事件和死亡未见剂量反应关系。
- LDL-C<70 mg/dL与大出血风险增加相关(校正OR 1.49;95%CI 1.21-1.84),在倾向性评分匹配队列及多项敏感性分析中一致。
- 替格瑞洛治疗患者LDL-C<88 mg/dL时出血风险增加,氯吡格雷治疗患者LDL-C<54 mg/dL时出血风险增加。
关键数值与推荐
- LDL-C<70 mg/dL为院内大出血风险增加的阈值(aOR 1.49;95%CI 1.21-1.84)。
- 替格瑞洛治疗者出血风险增高的LDL-C阈值为<88 mg/dL。
- 氯吡格雷治疗者出血风险增高的LDL-C阈值为<54 mg/dL。
临床怎么用
- 对接受PCI且使用高强度抗栓治疗的ACS患者,低LDL-C水平(尤其<70 mg/dL)需警惕院内大出血风险。
- 替格瑞洛治疗者LDL-C<88 mg/dL、氯吡格雷治疗者<54 mg/dL时应加强出血风险评估。
局限性
- 作为观察性注册研究,潜在混杂因素可能影响结果。
- 作者指出需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Emerging evidence has linked cholesterol metabolism with platelet responsiveness. We sought to examine the dose-response relationship between low-density lipoprotein cholesterol (LDL-C) and major in-hospital bleeds in acute coronary syndrome (ACS) patients. METHODS AND RESULTS: Among 42 378 ACS patients treated with percutaneous coronary intervention (PCI) enrolled in 240 hospitals in the Improving Care for Cardiovascular Disease in China-ACS project from 2014 to 2019, a total of 615 major bleeds, 218 ischaemic events, and 337 deaths were recorded. After controlling for baseline variables, a non-linear relationship was observed for major bleeds, with the higher risk at lower LDL-C levels. No dose-response relationship was identified for ischaemic events and mortality. A threshold value of LDL-C <70 mg/dL was associated with an increased risk for major bleeds (adjusted odds ratio: 1.49; 95% confidence interval: 1.21-1.84) in multivariable-adjusted logistic regression models and in propensity score-matched cohorts. The results were consistent in multiple sensitivity analyses. Among ticagrelor-treated patients, the LDL-C threshold for increased bleeding risk was observed at <88 mg/dL, whereas for clopidogrel-treated patients, the threshold was <54 mg/dL. Across a full spectrum of LDL-C levels, the treatment effect size associated with ticagrelor vs. clopidogrel on major bleeds favoured clopidogrel at lower LDL-C levels, but no difference at higher LDL-C levels. CONCLUSIONS: In a nationwide ACS registry, a non-linear association was identified between LDL-C levels and major in-hospital bleeds following PCI, with the higher risk at lower levels. As the potential for confounding may exist, further studies are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02306616.
引用
- Yang Q, Sun D, Pei C, et al. LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project. Eur Heart J. 2021. PMID: 34347859. doi:10.1093/eurheartj/ehab418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。